The primary purpose of this study is to evaluate the hypothesis that cixutumumab given in
combination with cisplatin and pemetrexed is superior to cisplatin and pemetrexed as
first-line therapy for patients with advanced nonsquamous non-small cell lung carcinoma
(NSCLC).